Potential methods to circumvent blocks in apoptosis in lymphomas

Current Opinion in Oncology

Volumn 14, Issue 5, 2002, Pages 490-503

  Ravi, Rajani ^a   Bedi, Atul ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CYTOCHROME C; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CELL FATE; CELL SURVIVAL; DNA DAMAGE; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; LYMPHOMA; MEMBRANE PERMEABILITY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; REVIEW;

APOPTOSIS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNE SYSTEM; LYMPHOCYTES; LYMPHOMA; MITOCHONDRIA; SIGNAL TRANSDUCTION;

EID: 0036739765     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200209000-00004     Document Type: Review

References (154)

1. Earnshaw WC, Martins LM, Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999, 68:383-424.
2. Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000, 102:1-4.
3. Gross A, McDonnell JM, Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13:1899-1911.
4. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
5. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309-1312.
6. Deveraux QL, Roy N, Stennicke HR, et al.: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998, 17:2215-2223.
7. Du C, Fang M, Li Y, Li L, Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
8. Verhagen AM, Ekert PG, Pakusch M, et al.: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
9. Suzuki Y, Imai Y, Nakayama H, et al.: A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001, 8:613-621.
10. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994, 76:959-962.
11. Brakebusch C, Nophar Y, Kemper O, et al.: Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signaling, but not induced shedding of the receptor. EMBO J 1992, 11:943-950.
12. Itoh N, Nagata S: A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993, 268:10932-10937.
13. Nagata S: Apoptosis by death factor. Cell 1997, 88:355-365.
14. Pan G, O'Rourke K, Chinnaiyan AM, et al.: The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
15. Screaton GR, Mongkolsapaya J, Xu XN, et al.: TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997, 7:693-696.
16. Pan G, Ni J, Wei YF, et al.: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-818.
17. Sheridan JP, Marsters SA, Pitti RM, et al.: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821.
18. Walczak H, Degli-Esposti MA, Johnson RS, et al.: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997, 16:5386-5397.
19. Wu GS, Burns TF, McDonald ER, III, et al.: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997, 17:141-143.
20. Pitti RM, Marsters SA, Ruppert S, et al.: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690.
21. Wiley SR, Schooley K, Smolak PJ, et al.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
22. Tartaglia LA, Ayres TM, Wong GH, et al.: A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993, 74:845-853.
23. Kischkel FC, Hellbardt S, Behrmann I, et al.: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995, 14:5579-5588.
24. Chinnaiyan AM, O'Rourke K, Tewari M, et al.: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512.
25. Boldin MP, Varfolomeev EE, Pancer Z, et al.: A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995, 270:7795-7798.
26. Boldin MP, Goncharov TM, Goltsev YV, et al.: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
27. Muzio M, Chinnaiyan AM, Kischkel FC, et al.: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827.
28. Medema JP, Scaffidi C, Kischkel FC, et al.: FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997, 16:2794-2804.
29. Muzio M, Stockwell BR, Stennicke HR, et al.: An induced proximity model for caspase-8 activation. J Biol Chem 1998, 273:2926-2930.
30. Kischkel FC, Lawrence DA, Tinel A, et al.: Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001, 276:46639-46646.
31. Scaffidi C, Fulda S, Srinivasan A, et al.: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17:1675-1687.
32. Wang K, Yin XM, Chao DT, et al.: Bid: a novel BH3 domain-only death agonist. Genes Dev 1996, 10:2859-2869.
33. Luo X, Budihardio I, Zou H, et al.: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
34. Li H, Zhu H, Xu CJ, et al.: Cleavage of Bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
35. Gross A, Yin XM, Wang K, et al.: Caspase cleaved Bid targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999, 274:1156-1163.
36. Roy S, Nicholson DW: Cross-talk in cell death signaling. J Exp Med 2000, 192:F21-F25.
37. Eskes R, Desagher S, Antonsson B, et al.: Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 2000, 20:929-935.
38. Wei MC, Lindsten T, Mootha VK, et al.: tBID, a membrane-targeted death ligand, oligomerizes Bak to release cytochrome c. Genes Dev 2000, 14:2060-2071.
39. Lindsten T, Ross AJ, King A, et al.: The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000, 6:1389-1399.
40. Wei MC, Zong WX, Cheng EH, et al.: Proapoptotic Bax and Bak: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
41. Ravi R, Bedi A: Requirement of Bax for TRAIL/Apo2L-induced Apoptosis of Colorectal Cancers: Synergism with Sulindac-mediated Inhibition of Bcl-x(L). Cancer Res 2002, 62:1583-1587.
42. LeBlanc H, Lawrence D, Varfolomeev E, et al.: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002, 8:274-281.
43. Deng Y, Lin Y, Wu X: TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002, 16:33-45.
44. Burns TF, el Deiry WS: Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001, 276:37879-37886.
45. Strasser A, O'Connor L, Dixit VM: Apoptosis signaling. Annu Rev Biochem 2000, 69:217-245.
46. Krammer PH: CD95's deadly mission in the immune system. Nature 2000, 407:789-795.
47. Leithauser F, Dhein J, Mechtersheimer G, et al.: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993, 69:415-429.
48. Li JH, Rosen D, Ronen D, et al.: The regulation of CD95 ligand expression and function in CTL. J Immunol 1998, 161:3943-3949.
49. Golstein P: Cell death: TRAIL and its receptors. Curr Biol 1997, 7:R750-R753.
50. Martinez-Lorenzo MJ, Alava MA, Gamen S, et al.: Involvement of APO2 ligand/-TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 1998, 28:2714-2725.
51. Thome M, Schneider P, Hofmann K, et al.: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521.
52. Irmler M, Thome M, Hahne M, et al.: Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
53. Srinivasula SM, Ahmad M, Ottilie S, et al.: FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 1997, 272:18542-18545.
54. Yeh WC, Itie A, Elia AJ, et al.: Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000, 12:633-642.
55. Desagher S, Osen-Sand A, Montessuit S, et al.: Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 2001, 8:601-611.
56. Cheng EH, Wei MC, Weiler S, et al.: BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing Bax- and Bak-mediated mitochondrial apoptosis. Mol Cell 2001, 8:705-711.
57. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
58. Deveraux QL, Takahashi R, Salvesen GS, et al.: X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304.
59. Roy N, Deveraux QL, Takahashi R, et al.: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997, 16:6914-6925.
60. Deveraux QL, Leo E, Stennicke HR, et al.: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999, 18:5242-5251.
61. Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3:221-227.
62. Senftleben U, Li ZW, Baud V, et al.: IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity 2001, 14:217-230.
63. Beg AA, Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996, 274:782-784.
64. Wang CY, Mayo MW, Baldwin AS, Jr.: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996, 274:784-787.
65. Van Antwerp DJ, Martin SJ, Kafri T, et al.: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996, 274:787-789.
66. Liu ZG, Hsu H, Goeddel DV, et al.: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996, 87:565-576.
67. Karin M, Ben Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-663.
68. Solan NJ, Miyoshi H, Carmona EM, et al.: RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem 2002, 277:1405-1418.
69. Senftleben U, Cao Y, Xiao G, et al.: Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499.
70. Wang D, Westerheide SD, Hanson JL, et al.: Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000, 275:32592-32597.
71. Zhong H, SuYang H, Erdjument-Bromage H, et al.: The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997, 89:413-424.
72. Sizemore N, Leung S, Stark GR: Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 1999, 19:4798-4805.
73. Madrid LV, Wang CY, Guttridge DC, et al.: Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000, 20:1626-1638.
74. Kreuz S, Siegmund D, Scheurich P, et al.: NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001, 21:3964-3973.
75. Hong SY, Yoon WH, Park JH, et al.: Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha-, CD40-, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem 2000, 275:18022-18028.
76. Wang CY, Mayo MW, Korneluk RG, et al.: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
77. Liston P, Roy N, Tamai K, et al.: Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996, 379:349-353.
78. Zong WX, Edelstein LC, Chen C, et al.: The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999, 13:382-387.
79. Chen C, Edelstein LC, Gelinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000, 20:2687-2695.
80. Bentires-Alj M, Dejardin E, Viatour P, et al.: Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 2001, 20:2805-2813.
81. Li ZW, Chu W, Hu Y, et al.: The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999, 189:1839-1845.
82. Van Parijs L, Ibraghimov A, Abbas AK: The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 1996, 4:321-328.
83. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C, Fuchs EJ, Bedi A: Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol. 2001, 3:409-416.
84. Tang G, Yang J, Minemoto Y, Lin A: Blocking caspase-3-mediated proteolysis of IKKbeta suppresses TNF-alpha-induced apoptosis. Mol Cell 2001, 8:1005-1016.
85. Reuther JY, Baldwin AS, Jr.: Apoptosis promotes a caspase-induced aminoterminal truncation of IkappaBalpha that functions as a stable inhibitor of NF-kappaB. J Biol Chem 1999, 274:20664-20670.
86. Barkett M, Xue D, Horvitz HR, et al.: Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem 1997, 272:29419-29422.
87. Ravi R, Bedi A, Fuchs EJ, et al.: CD95 (Fas)-induced caspase-mediated proteolysis of NF-kappaB. Cancer Res 1998, 58:882-886.
88. Levkau B, Scatena M, Giachelli CM, et al.: Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-kappa B loop. Nat Cell Biol 1999, 1:227-233.
89. Cheng EH, Kirsch DG, Clem RJ, et al.: Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997, 278:1966-1968.
90. Clem RJ, Cheng EH, Karp CL, et al.: Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci USA 1998, 95:554-559.
91. Fujita N, Nagahashi A, Nagashima K, et al.: Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases. Oncogene 1998, 17:1295-1304.
92. Clem RJ, Sheu TT, Richter BW, et al.: c-IAP1 is cleaved by caspases to produce a proapoptotic C-terminal fragment. J Biol Chem 2001, 276:7602-7608.
93. Boise LH, Noel PJ, Thompson CB: CD28 and apoptosis. Curr Opin Immunol 1995, 7:620-625.
94. Khoshnan A, Tindell C, Laux I, et al.: The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 2000, 165:1743-1754.
95. Van Parijs L, Ibraghimov A, Abbas AK: The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 1996, 4:321-328.
96. Lam KP, Rajewsky K: Rapid elimination of mature autoreactive B cells demonstrated by Cre-induced change in B cell antigen receptor specificity in vivo. Proc Natl Acad Sci USA 1998, 95:13171-13175.
97. Foy TM, Aruffo A, Bajorath J, et al.: Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996, 14:591-617.
98. Yan M, Marsters SA, Grewal IS, et al.: Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol 2000, 1:37-41.
99. Moore PA, Belvedere O, Orr A, et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
100. Mukhopadhyay A, Ni J, Zhai Y, et al.: Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 1999, 274:15978-15981.
101. Mackay F, Woodcock SA, Lawton P, et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
102. Khare SD, Sarosi I, Xia XZ, et al.: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000, 97:3370-3375.
103. Lee HH, Dadgostar H, Cheng Q, et al.: NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999, 96:9136-9141.
104. Lagresle C, Mondiere P, Bella C, et al.: Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis. J Exp Med 1996, 183:1377-1388.
105. Craxton A, Otipoby KL, Jiang A, et al.: Signal transduction pathways that regulate the fate of B lymphocytes. Adv Immunol 1999, 73:79-152.
106. Scott DW, Grdina T, Shi Y: T cells commit suicide, but B cells are murdered! J Immunol 1996, 156:2352-2356.
107. Strasser A, Harris AW, Jacks T, et al.: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994, 79:329-339.
108. Schuler M, Green DR: Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001, 29:684-688.
109. Ravi R, Mookerjee B, van Hensbergen Y, et al.: p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res 1998, 58:4531-4536.
110. Kuida K, Haydar TF, Kuan CY, et al.: Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998, 94:325-337.
111. Muller M, Wilder S, Bannasch D, et al.: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998, 188:2033-2045.
112. Wu GS, Burns TF, McDonald ER, et al.: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997, 17:141-143.
113. Fuchs EJ, McKenna KA, Bedi A: p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. Cancer Res 1997, 57:2550-2554.
114. Newton K, Strasser A: Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy. J Exp Med 2000, 191:195-200.
115. Kataoka T, Schroter M, Hahne M, et al.: FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998, 161:3936-3942.
116. Rich T, Allen RL, Wyllie AH: Defying death after DNA damage. Nature 2000, 407:777-783.
117. Muschen M, Rajewsky K, Kronke M, et al.: The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol 2002, 23:75-80.
118. Kramer MH, Hermans J, Wijburg E, et al.: Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998, 92:3152-3162.
119. Davis RE, Brown KD, Siebenlist U, et al.: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194:1861-1874.
120. Adida C, Haioun C, Gaulard P, et al.: Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000, 96:1921-1925.
121. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
122. Davis RE, Brown KD, Siebenlist U, et al.: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194:1861-1874.
123. Shipp MA, Ross KN, Tamayo P, et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8:68-74.
124. Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000, 256:42-49.
125. Shipp MA, Abeloff MD, Antman KH, et al.: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphomas: report of the jury. J Clin Oncol 1999, 17:423-429.
126. Davis TA, Maloney DG, Czerwinski DK, et al.: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin lymphoma without eradicating the malignant clone. Blood 1998, 92:1184-1190.
127. Renschler MF, Bhatt RR, Dower WJ, et al.: Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. Proc Natl Acad Sci USA 1994, 91:3623-3627.
128. Herold MJ, Kuss AW, Kraus C, et al.: Mitochondria-dependent caspase-9 activation is necessary for antigen receptor-mediated effector caspase activation and apoptosis in WEHI 231 lymphoma cells. J Immunol 2002, 168:3902-3909.
129. Berard M, Mondiere P, Casamayor-Palleja M, et al.: Mitochondria connects the antigen receptor to effector caspases during B cell receptor-induced apoptosis in normal human B cells. J Immunol 1999, 163:4655-4662.
130. Besnault L, Schrantz N, Auffredou MT, et al.: B cell receptor cross-linking triggers a caspase-8-dependent apoptotic pathway that is independent of the death effector domain of Fas-associated death domain protein. J Immunol 2001, 167:733-740.
131. Vuist WM, Levy R, Maloney DG: Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 1994, 83:899-906.
132. Timmerman JM, Levy R: The history of the development of vaccines for the treatment of lymphoma. Clin Lymphoma 2000, 1:129-139.
133. Maloney DG, Smith B, Rose A: Rituximab: mechanism of action and resistance. Semin Oncol 2002, 29:2-9.
134. Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001, 61:5137-5144.
135. Heusel JW, Wesselschmidt RL, Shresta S, et al.: Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994, 76:977-987.
136. Shresta S, MacIvor DM, Heusel JW, Russell JH, Ley TJ: Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci USA 1995, 92:5679-5683.
137. Metkar SS, Wang B, Aguilar-Santelises M, et al.: Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 2002, 16:417-428.
138. MacDonald G, Shi L, Vande VC, et al.: Mitochondria-dependent and -independent regulation of Granzyme B-induced apoptosis. J Exp Med 1999, 189:131-144.
139. Alimonti JB, Shi L, Baijal PK, et al.: Granzyme B induces Bid-mediated cytochrome c release and mitochondrial permeability transition. J Biol Chem 2001, 276:6974-6982.
140. Wang GQ, Wieckowski E, Goldstein LA, et al.: Resistance to granzyme B-mediated cytochrome c release in Bak-deficient cells. J Exp Med 2001, 194:1325-1337.
141. Heibein JA, Goping IS, Barry M, et al.: Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med 2000, 192:1391-1402.
142. Timmerman JM, Levy R: The history of the development of vaccines for the treatment of lymphoma. Clin Lymphoma 2000, 1:129-139.
143. Berdeja JG, Flinn IW: New approaches to blood and marrow transplantation for patients with low-grade lymphomas. Curr Opin Oncol 2001, 13:335-341.
144. Ratanatharathorn V, Uberti J, Karanes C, et al.: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin lymphoma. Blood 1994, 84:1050-1055.
145. Hale GA, Phillips GL: Allogeneic stem cell transplantation for the non-Hodgkin lymphomas and Hodgkin disease. Cancer Treat Rev 2000, 26:411-427.
146. Ashkenazi A, Pai RC, Fong S, et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
147. Chuntharapai A, Dodge K, Grimmer K, et al.: Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001, 166:4891-4898.
148. Ichikawa K, Liu W, Zhao L, et al.: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001, 7:954-960.
149. Jo M, Kim TH, Seol DW, et al.: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000, 6:564-567.
150. Lawrence D, Shahrokh Z, Marsters S, et al.: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001, 7:383-385.
151. Waters JS, Webb A, Cunningham D, et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin lymphoma. J Clin Oncol 2000, 18:1812-1823.
152. Wang JL, Liu D, Zhang ZJ, et al.: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000, 97:7124-7129.
153. Tzung SP, Kim KM, Basanez G, et al.: Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001, 3:183-191.
154. Degterev A, Lugovskoy A, Cardone M, et al.: Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001, 3:173-182.